Dengue Vaccine, Pharmaceutical Composition Comprising the Same, Nucleotide Sequence and Antibody Composition

Yee-Shin Lin (Inventor)

Research output: Patent

Abstract

The present invention relates to a dengue vaccine, a pharmaceutical composition comprising the same, a nucleotide sequence, and an antibody composition. The dengue vaccine of the present invention includes chimeric nonstructural protein 1, which comprises N-terminus of DV NS1 from amino-acid residues 1 to 270 and C-terminus of JEV NS1 from amino-acid residues 271 to 352 (designated DJ NS1).
Original languageEnglish
Patent number2428221
Publication statusPublished - 1800

Fingerprint

Dengue Vaccines
Amino Acids
Antibodies
Pharmaceutical Preparations
Proteins

Cite this

@misc{8fe6546e68b2450791ac071e703b5299,
title = "Dengue Vaccine, Pharmaceutical Composition Comprising the Same, Nucleotide Sequence and Antibody Composition",
abstract = "The present invention relates to a dengue vaccine, a pharmaceutical composition comprising the same, a nucleotide sequence, and an antibody composition. The dengue vaccine of the present invention includes chimeric nonstructural protein 1, which comprises N-terminus of DV NS1 from amino-acid residues 1 to 270 and C-terminus of JEV NS1 from amino-acid residues 271 to 352 (designated DJ NS1).",
author = "Yee-Shin Lin",
year = "1800",
language = "English",
type = "Patent",
note = "2428221",

}

TY - PAT

T1 - Dengue Vaccine, Pharmaceutical Composition Comprising the Same, Nucleotide Sequence and Antibody Composition

AU - Lin, Yee-Shin

PY - 1800

Y1 - 1800

N2 - The present invention relates to a dengue vaccine, a pharmaceutical composition comprising the same, a nucleotide sequence, and an antibody composition. The dengue vaccine of the present invention includes chimeric nonstructural protein 1, which comprises N-terminus of DV NS1 from amino-acid residues 1 to 270 and C-terminus of JEV NS1 from amino-acid residues 271 to 352 (designated DJ NS1).

AB - The present invention relates to a dengue vaccine, a pharmaceutical composition comprising the same, a nucleotide sequence, and an antibody composition. The dengue vaccine of the present invention includes chimeric nonstructural protein 1, which comprises N-terminus of DV NS1 from amino-acid residues 1 to 270 and C-terminus of JEV NS1 from amino-acid residues 271 to 352 (designated DJ NS1).

M3 - Patent

M1 - 2428221

ER -